<DOC>
	<DOCNO>NCT02430545</DOCNO>
	<brief_summary>The study also aim determine effect strong enzyme ( CYP3A4 ) inducer-rifampin- drug exposure Glasdegib . This study conduct healthy subject give single dose glasdegib period .</brief_summary>
	<brief_title>Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inducers</mesh_term>
	<criteria>Healthy female subject nonchildbearing potential and/or male subject , time screening , age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test . Female subject non childbearing potential must meet least one follow criterion : 1 . Achieved postmenopausal status , define follow : cessation regular menses least 12 consecutive month alternative pathological physiological cause ; AND serum folliclestimulating hormone ( FSH ) level confirm postmenopausal state ; 2 . Have undergone document hysterectomy and/or bilateral oophorectomy ; 3 . Have medically confirm ovarian failure . All female subject ( include female tubal ligation ) consider childbearing potential . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . A positive urine drug screen Screening supine 12 lead ECG demonstrate QTc &gt; 450 msec QRS interval &gt; 120 msec . If QTc exceed 450 msec , QRS exceed 120 msec , ECG repeat two time average three QTc QRS value use determine subject 's eligibility . Subjects family history myocardial infarction , congenital long QT syndrome , torsades de pointes clinically significant ventricular arrhythmia . Pregnant female subject ; breastfeed female subject ; male subject partner currently pregnant ; male subject able father child unwilling unable use two highly effective method contraception outline protocol duration study least 90 day last dose investigational product , refrain sperm donation duration study least 90 day last dose investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Glasdegib</keyword>
	<keyword>PF-04449913</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>CYP3A4 inducer</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>